Review Article

Significance and Prospect of Brf1 Overexpression

Liling Zheng*, Yongluan Lin, Zaifa Hong, Dongyan Shen and Shuping Zhong*

Published: 22 August, 2023 | Volume 7 - Issue 1 | Pages:

Brf1 (TFIIB-related factor 1) is a transcription factor, which specifically modulates the transcription of RNA polymerase III-dependent genes (RNA Pol III genes), such as tRNAs and 5S rRNA. The products of tRNAs and 5S rRNA transcription will be changed with the alteration of Brf1 expression. Whereas deregulation of Brf1 and RNA Pol III genes are tightly associated with cell proliferation and transformation, and tumorigenesis. In recent years, emerging studies indicate that Brf1 expression is increased in patients with cancers. In this review, we summarize the progress of the abnormal expression of Brf1 in different human cancers to explore an underlying mechanism and its clinical implication, as well as to prompt its application prospect. With the depth of the Brf1 study and the progress of biotechnology, the status of Brf1 expression may be used as a universal indicator of the early detection and prognosis observation of human cancers.

Read Full Article HTML DOI: 10.29328/journal.apps.1001043 Cite this Article Read Full Article PDF


Brf1; Pol III genes; Cancer; Survival; Prognosis


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
  2. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004 Aug;114(4):569-81. doi: 10.1172/JCI21358. PMID: 15314694; PMCID: PMC503772.
  3. White RJ. RNA polymerase III transcription and cancer. Oncogene. 2004 Apr 19;23(18):3208-16. doi: 10.1038/sj.onc.1207547. PMID: 15094770.
  4. Zhang Q, Jin J, Zhong Q, Yu X, Levy D, Zhong S. ERα mediates alcohol-induced deregulation of Pol III genes in breast cancer cells. Carcinogenesis. 2013 Jan;34(1):28-37. doi: 10.1093/carcin/bgs316. Epub 2012 Oct 10. PMID: 23054611; PMCID: PMC3534194.
  5. Zhong S, Zhang C, Johnson DL. Epidermal growth factor enhances cellular TATA binding protein levels and induces RNA polymerase I- and III-dependent gene activity. Mol Cell Biol. 2004 Jun;24(12):5119-29. doi: 10.1128/MCB.24.12.5119-5129.2004. PMID: 15169879; PMCID: PMC419868.
  6. Zhang Q, Zhong Q, Evans AG, Levy D, Zhong S. Phosphorylation of histone H3 serine 28 modulates RNA polymerase III-dependent transcription. Oncogene. 2011 Sep 15;30(37):3943-52. doi: 10.1038/onc.2011.105. Epub 2011 Apr 4. PMID: 21460852; PMCID: PMC3134635.
  7. Zhong Q, Shi G, Zhang Q, Zhang Y, Levy D, Zhong S. Role of phosphorylated histone H3 serine 10 in DEN-induced deregulation of Pol III genes and cell proliferation and transformation. Carcinogenesis. 2013 Nov;34(11):2460-9. doi: 10.1093/carcin/bgt219. Epub 2013 Jun 17. PMID: 23774401; PMCID: PMC3888355.
  8. Johnson SA, Dubeau L, Johnson DL. Enhanced RNA polymerase III-dependent transcription is required for oncogenic transformation. J Biol Chem. 2008 Jul 11;283(28):19184-91. doi: 10.1074/jbc.M802872200. Epub 2008 May 1. PMID: 18456653; PMCID: PMC2443659.
  9. Wu T, Zhang D, Lin M, Yu L, Dai T, Li S, Yu F, Lu L, Zheng L, Zhong S. Exploring the Role and Mechanism of pAMPKα-Mediated Dysregulation of Brf1 and RNA Pol III Genes. Oxid Med Cell Longev. 2021 Apr 20;2021:5554932. doi: 10.1155/2021/5554932. PMID: 33995823; PMCID: PMC8081602.
  10. Hong Z, Fang Z, Lei J, Shi G, Zhang Y, He Z, Li B W, Zhong S. The significance of Runx2 mediating alcohol-induced Brf1 expression and RNA Pol III gene transcription. Chem Biol Interact. 2020 May 25;323:109057. doi: 10.1016/j.cbi.2020.109057. Epub 2020 Mar 18. PMID: 32198086; PMCID: PMC7261693.
  11. Lin M, Huang C, Ren W, Chen J, Xia N, Zhong S. Mitogen- and Stress-Activated Protein Kinase 1 Mediates Alcohol-Upregulated Transcription of Brf1 and tRNA Genes to Cause Phenotypic Alteration. Oxid Med Cell Longev. 2020 Jun 27;2020:2067959. doi: 10.1155/2020/2067959. PMID: 32685086; PMCID: PMC7336232.
  12. Zhong S, Machida K, Tsukamoto H, Johnson DL. Alcohol induces RNA polymerase III-dependent transcription through c-Jun by co-regulating TATA-binding protein (TBP) and Brf1 expression. J Biol Chem. 2011 Jan 28;286(4):2393-401. doi: 10.1074/jbc.M110.192955. Epub 2010 Nov 24. PMID: 21106530; PMCID: PMC3024733.
  13. Zheng L, Lin Y, Zhong S. ROS Signaling-Mediated Novel Biological Targets: Brf1 and RNA Pol III Genes. Oxid Med Cell Longev. 2021 Oct 4;2021:5888432. doi: 10.1155/2021/5888432. PMID: 34646425; PMCID: PMC8505076.
  14. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006 Dec;13(12):1097-101. doi: 10.1038/nsmb1167. Epub 2006 Nov 12. PMID: 17099701.
  15. Fang Z, Yi Y, Shi G, Li S, Chen S, Lin Y, Li Z, He Z, Li W, Zhong S. Role of Brf1 interaction with ERα, and significance of its overexpression, in human breast cancer. Mol Oncol. 2017 Dec;11(12):1752-1767. doi: 10.1002/1878-0261.12141. Epub 2017 Oct 27. PMID: 28972307; PMCID: PMC5709663.
  16. Zhong Q, Xi S, Liang J, Shi G, Huang Y, Zhang Y, Levy D, Zhong S. The significance of Brf1 overexpression in human hepatocellular carcinoma. Oncotarget. 2016 Feb 2;7(5):6243-54. doi: 10.18632/oncotarget.6668. PMID: 26701855; PMCID: PMC4868753.
  17. Zhang Y, Wu H, Yang F, Ning J, Li M, Zhao C, Zhong S, Gu K, Wang H. Prognostic Value of the Expression of DNA Repair-Related Biomarkers Mediated by Alcohol in Gastric Cancer Patients. Am J Pathol. 2018 Feb;188(2):367-377. doi: 10.1016/j.ajpath.2017.10.010. Epub 2018 Jan 10. PMID: 29331492; PMCID: PMC5974541.
  18. Loveridge CJ, Slater S, Campbell KJ, Nam NA, Knight J, Ahmad I, Hedley A, Lilla S, Repiscak P, Patel R, Salji M, Fleming J, Mitchell L, Nixon C, Strathdee D, Neilson M, Ntala C, Bryson S, Zanivan S, Edwards J, Robson CN, Goodyear CS, Blyth K, Leung HY. BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene. 2020 Feb;39(8):1797-1806. doi: 10.1038/s41388-019-1106-x. Epub 2019 Nov 18. Erratum in: Oncogene. 2019 Dec 19;: PMID: 31740786; PMCID: PMC7033044.
  19. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8. PMID: 31912902.
  20. Jordan VC. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 1993 Oct;110(2):507-17. doi: 10.1111/j.1476-5381.1993.tb13840.x. PMID: 8242225; PMCID: PMC2175926.
  21. Zhong Q, Shi G, Zhang Q, Lu L, Levy D, Zhong S. Tamoxifen represses alcohol-induced transcription of RNA polymerase III-dependent genes in breast cancer cells. Oncotarget. 2014 Dec 15;5(23):12410-7. doi: 10.18632/oncotarget.2678. PMID: 25400119; PMCID: PMC4322994.
  22. Deandrea S, Talamini R, Foschi R, Montella M, Dal Maso L, Falcini F, La Vecchia C, Franceschi S, Negri E. Alcohol and breast cancer risk defined by estrogen and progesterone receptor status: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2025-8. doi: 10.1158/1055-9965.EPI-08-0157. PMID: 18708394.
  23. MacMahon B. Epidemiology and the causes of breast cancer. Int J Cancer. 2006 May 15;118(10):2373-8. doi: 10.1002/ijc.21404. PMID: 16358260.
  24. Suzuki R, Orsini N, Mignone L, Saji S, Wolk A. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies. Int J Cancer. 2008 Apr 15;122(8):1832-41. doi: 10.1002/ijc.23184. Erratum in: Int J Cancer. 2008 Aug 15;123(4):981. PMID: 18067133.
  25. Wang S, Xu M, Li F, Wang X, Bower KA, Frank JA, Lu Y, Chen G, Zhang Z, Ke Z, Shi X, Luo J. Ethanol promotes mammary tumor growth and angiogenesis: the involvement of chemoattractant factor MCP-1. Breast Cancer Res Treat. 2012 Jun;133(3):1037-48. doi: 10.1007/s10549-011-1902-7. Epub 2011 Dec 9. PMID: 22160640; PMCID: PMC3323664.
  26. Wong AW, Dunlap SM, Holcomb VB, Nunez NP. Alcohol promotes mammary tumor development via the estrogen pathway in estrogen receptor alpha-negative HER2/neu mice. Alcohol Clin Exp Res. 2012 Apr;36(4):577-87. doi: 10.1111/j.1530-0277.2011.01654.x. Epub 2011 Oct 7. PMID: 21981381.
  27. Zhong Q, Shi G, Zhang Y, Levy D, Zhong S. Elk1 and AP-1 sites in the TBP promoter mediate alcohol-induced deregulation of Pol III-dependent genes. Gene. 2013 Aug 15;526(1):54-60. doi: 10.1016/j.gene.2013.02.004. Epub 2013 Feb 20. PMID: 23454483; PMCID: PMC3715583.
  28. Yi Y, Huang C, Zhang Y, Tian S, Lei J, Chen S, Shi G, Wu Z, Xia N, Zhong S. Exploring a common mechanism of alcohol-induced deregulation of RNA Pol III genes in liver and breast cells. Gene. 2017 Aug 30;626:309-318. doi: 10.1016/j.gene.2017.05.048. Epub 2017 May 25. PMID: 28552569; PMCID: PMC5521807.
  29. Duncan JA, Reeves JR, Cooke TG. BRCA1 and BRCA2 proteins: roles in health and disease. Mol Pathol. 1998 Oct;51(5):237-47. doi: 10.1136/mp.51.5.237. PMID: 10193517; PMCID: PMC395646.
  30. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004 Nov;95(11):866-71. doi: 10.1111/j.1349-7006.2004.tb02195.x. PMID: 15546503.
  31. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA. 2011 Nov 2;306(17):1884-90. doi: 10.1001/jama.2011.1590. PMID: 22045766; PMCID: PMC3292347.
  32. Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer. 2007 Aug 6;7:152. doi: 10.1186/1471-2407-7-152. PMID: 17683622; PMCID: PMC1959234.
  33. Zhong Q, Shi G, Zhang Y, Lu L, Levy D, Zhong S. Alteration of BRCA1 expression affects alcohol-induced transcription of RNA Pol III-dependent genes. Gene. 2015 Feb 1;556(1):74-9. doi: 10.1016/j.gene.2014.11.009. Epub 2014 Nov 8. PMID: 25447904; PMCID: PMC4272617.
  34. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997 May 30;89(5):755-64. doi: 10.1016/s0092-8674(00)80258-5. PMID: 9182763.
  35. Ferrari N, McDonald L, Morris JS, Cameron ER, Blyth K. RUNX2 in mammary gland development and breast cancer. J Cell Physiol. 2013 Jun;228(6):1137-42. doi: 10.1002/jcp.24285. PMID: 23169547.
  36. Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021 Nov;15(11):1295-1307. doi: 10.1080/17474124.2021.1991792. Epub 2021 Oct 22. PMID: 34624198.
  37. Lieber CS. Hepatic, metabolic, and nutritional disorders of alcoholism: from pathogenesis to therapy. Crit Rev Clin Lab Sci. 2000 Dec;37(6):551-84. doi: 10.1080/10408360091174312. PMID: 11192332.
  38. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007 Aug;7(8):599-612. doi: 10.1038/nrc2191. PMID: 17646865.
  39. Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer. 2004 Sep 1;101(5):1009-17. doi: 10.1002/cncr.20427. PMID: 15329910.
  40. Purohit V, Khalsa J, Serrano J. Mechanisms of alcohol-associated cancers: introduction and summary of the symposium. Alcohol. 2005 Apr;35(3):155-60. doi: 10.1016/j.alcohol.2005.05.001. PMID: 16054976.
  41. Brar G, Greten TF, Graubard BI, McNeel TS, Petrick JL, McGlynn KA, Altekruse SF. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. Hepatol Commun. 2020 Aug 9;4(10):1541-1551. doi: 10.1002/hep4.1564. PMID: 33024922; PMCID: PMC7527688.
  42. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013 Apr 2;6(269):pl1. doi: 10.1126/scisignal.2004088. PMID: 23550210; PMCID: PMC4160307.
  43. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401-4. doi: 10.1158/2159-8290.CD-12-0095. Erratum in: Cancer Discov. 2012 Oct;2(10):960. PMID: 22588877; PMCID: PMC3956037.
  44. Reguart N, Marin E, Remon J, Reyes R, Teixido C. In Search of the Long-Desired 'Copernican Therapeutic Revolution' in Small-Cell Lung Cancer. Drugs. 2020 Feb;80(3):241-262. doi: 10.1007/s40265-019-01240-8. PMID: 31912414.
  45. Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the management of lung cancer. J Thorac Dis. 2013 Oct;5 Suppl 5(Suppl 5):S463-78. doi: 10.3978/j.issn.2072-1439.2013.08.43. PMID: 24163740; PMCID: PMC3804871.
  46. Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, Jakopović M, Brčić L, Knežević J. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. J Pers Med. 2021 Oct 27;11(11):1102. doi: 10.3390/jpm11111102. PMID: 34834454; PMCID: PMC8624402.
  47. Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016 Jul 15;48(7):e245. doi: 10.1038/emm.2016.81. PMID: 27416781; PMCID: PMC4973318.
  48. McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014 Nov;11(11):664-74. doi: 10.1038/nrgastro.2014.143. Epub 2014 Aug 19. PMID: 25134511.
  49. Asif S, Teply BA. Biomarkers for Treatment Response in Advanced Prostate Cancer. Cancers (Basel). 2021 Nov 16;13(22):5723. doi: 10.3390/cancers13225723. PMID: 34830878; PMCID: PMC8616385.
  50. Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021 Sep 18;398(10305):1075-1090. doi: 10.1016/S0140-6736(21)00950-8. Epub 2021 Aug 6. PMID: 34370973.
  51. SEER* Explorer Application. seer.cancer.gov. https://seer.cancer.gov/statistics-network/explorer/application.html
  52. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8. Erratum in: Lancet. 2019 Jun 22;393(10190):e44. PMID: 30496104; PMCID: PMC6227754.
  53. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, Pletcher MA, Smith AE, Tang K, Yuan CW, Brown JC, Friedman J, He J, Heuton KR, Holmberg M, Patel DJ, Reidy P, Carter A, Cercy K, Chapin A, Douwes-Schultz D, Frank T, Goettsch F, Liu PY, Nandakumar V, Reitsma MB, Reuter V, Sadat N, Sorensen RJD, Srinivasan V, Updike RL, York H, Lopez AD, Lozano R, Lim SS, Mokdad AH, Vollset SE, Murray CJL. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018 Nov 10;392(10159):2052-2090. doi: 10.1016/S0140-6736(18)31694-5. Epub 2018 Oct 16. PMID: 30340847; PMCID: PMC6227505.
  54. Macke AJ, Petrosyan A. Alcohol and Prostate Cancer: Time to Draw Conclusions. Biomolecules. 2022 Feb 28;12(3):375. doi: 10.3390/biom12030375. PMID: 35327568; PMCID: PMC8945566.
  55. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. PMID: 25651787.
  56. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017 Apr;66(4):683-691. doi: 10.1136/gutjnl-2015-310912. Epub 2016 Jan 27. PMID: 26818619.
  57. Zygulska AL, Pierzchalski P. Novel Diagnostic Biomarkers in Colorectal Cancer. Int J Mol Sci. 2022 Jan 13;23(2):852. doi: 10.3390/ijms23020852. PMID: 35055034; PMCID: PMC8776048.
  58. Ettrich TJ, Seufferlein T. Systemic Therapy for Metastatic Pancreatic Cancer. Curr Treat Options Oncol. 2021 Oct 19;22(11):106. doi: 10.1007/s11864-021-00895-4. PMID: 34665339; PMCID: PMC8526424.
  59. Bagante F, Spolverato G, Cucchetti A, Gani F, Popescu I, Ruzzenente A, Marques HP, Aldrighetti L, Gamblin TC, Maithel SK, Sandroussi C, Bauer TW, Shen F, Poultsides GA, Marsh JW, Guglielmi A, Pawlik TM. Defining when to offer operative treatment for intrahepatic cholangiocarcinoma: A regret-based decision curves analysis. Surgery. 2016 Jul;160(1):106-117. doi: 10.1016/j.surg.2016.01.023. Epub 2016 Apr 1. PMID: 27046702.
  60. Farges O, Fuks D, Boleslawski E, Le Treut YP, Castaing D, Laurent A, Ducerf C, Rivoire M, Bachellier P, Chiche L, Nuzzo G, Regimbeau JM. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011 Nov;254(5):824-29; discussion 830. doi: 10.1097/SLA.0b013e318236c21d. PMID: 22042474.


Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?